Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

No detectable increase in pregnancy risks after GLP-1 exposure around conception, largest review to date finds (opens in a new tab)

medicalxpress.com · 2026-10-05

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

No detectable increase in pregnancy risks after GLP-1 exposure around conception, largest review to date finds

medicalxpress.com · 2026-10-05

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Four of five claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 4 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe study was a systematic review and meta-analysis published in Med, led by researchers at City St George's, and it pooled data from 10 studies.View evidenceHide evidence

As statedlargest systematic review and meta-analysis on this topic to date

Why this verdict

The profile supports that the paper was a systematic review and random-effects meta-analysis of observational studies and that 10 studies were included. However, the abstract-level profile does not verify the journal 'Med,' the named lead institution, or the claim that it was the largest systematic review/meta-analysis on this topic to date.

1

Study evidence

Pooled analyses did not detect a clearly increased risk associated with periconceptional GLP-1 RA exposure for miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy overall, gestational diabetes, abnormal fetal growth, or excess gestational weight gain.

“This systematic review and meta-analysis assesses whether exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy or the periconceptional period is associated with adverse maternal and perinatal outcomes.”
2

Study evidence

Pooled analyses did not show a clearly detectable increase in miscarriage or intrauterine death in pregnancies with periconceptional GLP-1 RA exposure versus unexposed pregnancies.

“Random-effects meta-analyses and subgroup analyses by indication were performed.”
Claim 2 of 5SupportedExposure to GLP-1 weight-loss and diabetes drugs around conception is not linked to a clearly detectable increase in adverse outcomes for mothers or babies, according to the largest study of its kind.View evidenceHide evidence

As statedlargest study of its kind

Why this verdict

The abstract-level profile supports the central headline framing: pooled observational evidence did not identify a clearly detectable increase in adverse maternal or perinatal outcomes after periconceptional GLP-1 RA exposure. The headline is appropriately hedged as absence of a clearly detectable increase rather than proof of safety. The 'largest study of its kind' wording is not directly established in the abstract profile, though the profile does support a large corpus of 10 studies and 2,118,215 women.

1

Study evidence

Pooled analyses did not detect a clearly increased risk associated with periconceptional GLP-1 RA exposure for miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy overall, gestational diabetes, abnormal fetal growth, or excess gestational weight gain.

“This systematic review and meta-analysis assesses whether exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy or the periconceptional period is associated with adverse maternal and perinatal outcomes.”
2

Study evidence

Pooled analyses did not show a clearly detectable increase in miscarriage or intrauterine death in pregnancies with periconceptional GLP-1 RA exposure versus unexposed pregnancies.

“Random-effects meta-analyses and subgroup analyses by indication were performed.”
Claim 3 of 5SupportedThe analysis included 2,118,215 pregnancies, including 8,325 pregnancies exposed to a GLP-1 receptor agonist around conception and within six months before a positive pregnancy test.View evidenceHide evidence

As stated2,118,215 pregnancies; 8,325 exposed pregnancies

Why this verdict

The profile reports 10 studies including 2,118,215 women, with 8,325 exposed and 2,109,890 unexposed, and defines exposure as GLP-1 RA exposure within 6 months before a positive pregnancy test. This matches the story’s numerical and exposure-window claim.

1

Study evidence

Pooled analyses did not detect a clearly increased risk associated with periconceptional GLP-1 RA exposure for miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy overall, gestational diabetes, abnormal fetal growth, or excess gestational weight gain.

“This systematic review and meta-analysis assesses whether exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy or the periconceptional period is associated with adverse maternal and perinatal outcomes.”
2

Study evidence

Pooled analyses did not show a clearly detectable increase in miscarriage or intrauterine death in pregnancies with periconceptional GLP-1 RA exposure versus unexposed pregnancies.

“Random-effects meta-analyses and subgroup analyses by indication were performed.”
Claim 4 of 5SupportedResearchers found no clearly detectable increase in the risk of miscarriage, stillbirth, congenital anomalies, preterm birth, gestational diabetes, high blood pressure disorders of pregnancy, excessive maternal weight gain, or babies being unusually small or large at birth compared with unexposed pregnancies.View evidenceHide evidence

As statedno clearly detectable increase

Why this verdict

The abstract-level profile states that pooled estimates did not show a clearly detectable increase in miscarriage or intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy, gestational diabetes, abnormal fetal growth, or excess gestational weight gain. This supports the story’s outcome list and associational framing, with 'stillbirth' corresponding broadly to intrauterine death.

1

Study evidence

Pooled analyses did not show a clearly detectable increase in miscarriage or intrauterine death in pregnancies with periconceptional GLP-1 RA exposure versus unexposed pregnancies.

“Random-effects meta-analyses and subgroup analyses by indication were performed.”
Claim 5 of 5SupportedThe authors caution that the findings should not be interpreted as proof that GLP-1 receptor agonists are safe to use during pregnancy, because the available evidence comes from observational studies and cannot establish cause and effect.View evidenceHide evidence

Why this verdict

The profile explicitly says the findings do not establish safety because the evidence is observational and subject to issues such as residual confounding, heterogeneity, and limited datasets. The story’s caveat that the results are not proof of safety and cannot establish cause and effect is supported.

1

Study evidence

Pooled analyses did not detect a clearly increased risk associated with periconceptional GLP-1 RA exposure for miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy overall, gestational diabetes, abnormal fetal growth, or excess gestational weight gain.

“This systematic review and meta-analysis assesses whether exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy or the periconceptional period is associated with adverse maternal and perinatal outcomes.”
2

Study evidence

Pooled analyses did not show a clearly detectable increase in miscarriage or intrauterine death in pregnancies with periconceptional GLP-1 RA exposure versus unexposed pregnancies.

“Random-effects meta-analyses and subgroup analyses by indication were performed.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • A lower pooled estimate for preeclampsia was observed, but it was based on only two datasets and should be interpreted cautiously.

    The story mentions high blood pressure disorders generally but does not report the specific preeclampsia finding or its caution that the estimate came from only two datasets.

    From random-effects meta-analysis of observational studies; subgroup analysis by indication

  • Heterogeneity across included studies and residual confounding limit causal or safety inferences.

    The story acknowledges observational evidence and lack of causal proof, but the supplied caveats do not specifically mention heterogeneity across studies or residual confounding, which are material limitations in the paper profile.

    From Systematic review of observational studies with meta-analysis; random-effects meta-analysis of observational studies; su

  • Some outcomes were supported by limited datasets, reducing certainty for specific pooled estimates.

    The paper profile notes limited datasets for several outcomes, including preeclampsia based on two datasets and the congenital-malformation sensitivity analysis based on the same four studies. The story’s caveats do not mention this limitation.

    From random-effects meta-analysis of observational studies; subgroup analysis by indication; sensitivity analysis — alternati

  • The exposure-window sensitivity analysis for congenital anomalies was not independent of the primary congenital-malformation analysis.

    The story does not discuss the sensitivity analysis or the limitation that it reused the same four studies as the primary congenital-malformation analysis.

    From sensitivity analysis — alternative exposure window

  • Subgroup analyses by indication showed no clearly detectable differences.

    The profile reports subgroup analyses by indication, but the story presentation does not mention this analysis.

    From random-effects meta-analysis of observational studies; subgroup analysis by indication

5 things the story did carry across
  • The paper is a systematic review and meta-analysis of observational studies comparing GLP-1 RA-exposed and unexposed pregnancies.
  • The review included 10 studies and 2,118,215 women/pregnancies, including 8,325 exposed to GLP-1 receptor agonists.
  • The primary exposure definition was GLP-1 RA exposure within 6 months before a positive pregnancy test.
  • Pooled estimates did not identify a clearly detectable increase in multiple adverse maternal and perinatal outcomes.
  • The authors caution that absence of a detectable increased risk does not establish safety, because the evidence is observational.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataQuantitatively synthesize associations between GLP-1 RA exposure and specific obstetric/perinatal outcomes via random-effects meta-analysis (including subgroup analyses by indication).random-effects meta-analysis of observational studies; subgroup analysis by indicationExpand

In plain English

Systematic review and random-effects meta-analyses of observational studies comparing pregnancies with periconceptional GLP-1 RA exposure versus unexposed pregnancies (exposure defined up to 6 months before a positive pregnancy test). Ten studies (2,118,215 women; 8,325 exposed, 2,109,890 unexposed) were pooled across multiple maternal and perinatal outcomes. Pooled estimates did not show a clearly detectable increase in miscarriage or intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy overall, gestational diabetes, abnormal fetal growth (FGR/SGA/LGA), or excess gestational weight gain. A lower pooled estimate for preeclampsia was observed (OR 0.87, 95% CI 0.78–0.98; p = 0.02) but was based on two datasets and should be interpreted cautiously. Subgroup analyses by indication did not show clearly detectable differences. The authors note that the absence of detectable increased risk in pooled observational data does not establish safety because of heterogeneity, residual confounding, and limited datasets.

Key findings

  • Pooled analyses did not show a clearly detectable increase in miscarriage or intrauterine death in pregnancies with periconceptional GLP-1 RA exposure versus unexposed pregnancies.
  • Pooled analyses did not show a clearly detectable increase in congenital anomalies.
“Random-effects meta-analyses and subgroup analyses by indication were performed.”
What this piece can’t prove
  • Heterogeneity across included observational studies.
  • Potential residual confounding inherent to non-randomized observational evidence.
  • Limited datasets for several outcomes; some pooled estimates (e.g., preeclampsia) derived from only two datasets and should be interpreted cautiously.
  • Sensitivity exposure-window analysis for congenital anomalies was not independent (used same four studies as primary analysis).
2secondary dataAssess whether periconceptional or pregnancy exposure to GLP-1 receptor agonists is associated with adverse maternal and perinatal outcomes using a systematic review of observational studies.Systematic review of observational studies with meta-analysisExpand

In plain English

Systematic review and random-effects meta-analysis of observational studies assessing whether periconceptional or pregnancy exposure to GLP-1 receptor agonists is associated with adverse maternal or perinatal outcomes. Searches of Medline, Embase, and the Cochrane Library identified 10 studies (2,118,215 women; 8,325 exposed, 2,109,890 unexposed). Pooled analyses did not identify a clearly detectable increase in miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy, gestational diabetes, abnormal fetal growth (SGA/LGA/FGR), or excess gestational weight gain. A lower pooled estimate for preeclampsia was observed (OR 0.87, 95% CI 0.78–0.98; p = 0.02) based on two datasets. The authors note heterogeneity, residual confounding, and limited datasets limit inferences about safety.

Key findings

  • Pooled analyses did not detect a clearly increased risk associated with periconceptional GLP-1 RA exposure for miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy overall, gestational diabetes, abnormal fetal growth, or excess gestational weight gain.
  • Preeclampsia: pooled estimate suggested a lower odds (OR 0.87, 95% CI 0.78–0.98; p = 0.02).OR 0.87 (95% CI 0.78–0.98)
“This systematic review and meta-analysis assesses whether exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy or the periconceptional period is associated with adverse maternal and perinatal outcomes.”
What this piece can’t prove
  • Heterogeneity across included observational studies (designs, populations, exposure ascertainment) as noted by the authors.
  • Residual confounding inherent to observational data may affect pooled estimates.
  • Limited datasets for some outcomes (e.g., preeclampsia estimate based on two datasets; congenital-malformation sensitivity analysis based on four studies).

1 further detail could not be confirmed from the summary.

3secondary dataEvaluate robustness via sensitivity analysis using an alternative exposure window (90 days before conception through end of first trimester) and clarify non-independence of that analysis relative to the primary congenital-malformation analysis.sensitivity analysis — alternative exposure windowExpand

In plain English

A sensitivity analysis redefined the periconceptional GLP-1 RA exposure window to 90 days before conception through the end of the first trimester. The authors report that this exposure-window sensitivity analysis used the same four studies as their primary congenital-malformation analysis and therefore was not independent of that primary analysis.

Key findings

  • The exposure-window sensitivity analysis (90 days before conception through end of first trimester) used the same four studies as the primary congenital-malformation analysis and therefore was not independent.
“The exposure-window sensitivity analysis, covering 90 days before conception through the end of the first trimester, used the same four studies as the primary congenital-malformation analysis and therefore was not independent.”
What this piece can’t prove
  • Sensitivity analysis reused the same four studies as the primary congenital-malformation analysis and thus is not an independent test of robustness.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 39 candidate papers

And 33 more candidates considered.